{"id":"80118806-7d6e-5e02-975c-005d1c1fbe54","stable_key":"f2ec2007-88ff-5a96-a73b-8b5085e9cea9:mbz-human-dose-escalation","predicate":"causes","statement":"In 24 patients with newly diagnosed high-grade glioma given mebendazole with adjuvant temozolomide, four patients at 200 milligrams per kilogram per day developed elevated grade 3 alanine aminotransferase or aspartate transaminase after one month which reversed with lower dosing or discontinuation, plasma levels were variable but generally increased with dose, and mebendazole at doses up to 200 milligrams per kilogram demonstrated long-term safety and acceptable toxicity.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"positive","is_public":true,"mechanism_event_id":"6ab67474-fa11-52f9-8746-41aa8c278d2d","mechanism_event_label":"At the highest dose one patient in six developed liver enzyme rises that reversed on stopping.","subject":{"id":"f8582a13-fc2e-5127-a61f-5b0594e54069","slug":"mebendazole","display_name":"Mebendazole","entity_type_key":"drug"},"object":{"id":"b45f0197-4a2c-5f72-a085-20403e9db300","slug":"transaminase-elevation","display_name":"Elevation of alanine and aspartate aminotransferase","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"6ab67474-fa11-52f9-8746-41aa8c278d2d","stable_key":"f2ec2007-88ff-5a96-a73b-8b5085e9cea9:mbz-human-dose-escalation-event","event_type":"observed_intervention","label":"At the highest dose one patient in six developed liver enzyme rises that reversed on stopping.","description":"In 24 patients with newly diagnosed high-grade glioma given mebendazole with adjuvant temozolomide, four patients at 200 milligrams per kilogram per day developed elevated grade 3 alanine aminotransferase or aspartate transaminase after one month which reversed with lower dosing or discontinuation, plasma levels were variable but generally increased with dose, and mebendazole at doses up to 200 milligrams per kilogram demonstrated long-term safety and acceptable toxicity.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"85eea0d4-b97f-5850-b259-734a9f44e65c","slug":"temozolomide","display_name":"Temozolomide","entity_type_key":"drug"},"role":"co_administered_drug","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"f979ae65-df08-5268-a3e6-316e9151979f","slug":"hepatotoxicity","display_name":"Drug-induced hepatitis and hepatocellular cytolysis","entity_type_key":"cellular_process"},"role":"related_harm","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"42246bab-bc05-54aa-bed7-28c5ea57976c","slug":"plasma-concentration","display_name":"Plasma concentration of mebendazole","entity_type_key":"cellular_process"},"role":"co_measured","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"f8582a13-fc2e-5127-a61f-5b0594e54069","slug":"mebendazole","display_name":"Mebendazole","entity_type_key":"drug"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""},{"entity":{"id":"b45f0197-4a2c-5f72-a085-20403e9db300","slug":"transaminase-elevation","display_name":"Elevation of alanine and aspartate aminotransferase","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":4,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/mebendazole-research/33506200.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"ab5f2c1d14ccb7fa9f690201326bdbfcab3e07758bc78b76ff9adec2ca774ec6\", \"start_char\": 0, \"end_char\": 1712, \"text_sha256\": \"ab5f2c1d14ccb7fa9f690201326bdbfcab3e07758bc78b76ff9adec2ca774ec6\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Single-centre dose-escalation and safety study in 24 patients with newly diagnosed high-grade glioma","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Oral mebendazole at 25, 50, 100 and 200 milligrams per kilogram per day with adjuvant temozolomide, with trough plasma levels at 4, 8 and 16 weeks","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"The only human oncology record here. It is a single-arm dose-escalation and safety study without a control group, so the survival figures cannot be read as efficacy.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Mebendazole research collection; topical membership is not evidence of a direct clinical effect, and mebendazole is recorded separately from albendazole, from the benzimidazole class and from its own crystal forms.","comparator":null,"unit":null,"notes":"","entity":{"slug":"mebendazole","display_name":"Mebendazole","entity_type_key":"drug"}},{"dimension":"organism","value_text":"Human","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"At the highest dose one patient in six developed liver enzyme rises that reversed on stopping.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[mbz-p33506200] Mebendazole and temozolomide in patients with newly diagnosed high-grade gliomas: results of a phase 1 clinical trial. (2021). https://pubmed.ncbi.nlm.nih.gov/33506200/ DOI: 10.1093/noajnl/vdaa154","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Brain","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"71c37c8c-9570-5891-aac7-35f99459d288","evidence_kind":"source_excerpt","locator":"Lines 576-587","start_line":576,"end_line":587,"excerpt":"### mbz-human-dose-escalation\nIn 24 patients with newly diagnosed high-grade glioma given mebendazole with adjuvant temozolomide, four patients at 200 milligrams per kilogram per day developed elevated grade 3 alanine aminotransferase or aspartate transaminase after one month which reversed with lower dosing or discontinuation, plasma levels were variable but generally increased with dose, and mebendazole at doses up to 200 milligrams per kilogram demonstrated long-term safety and acceptable toxicity.\nCondition category: normal\nnutrient_topic: Mebendazole research collection; topical membership is not evidence of a direct clinical effect, and mebendazole is recorded separately from albendazole, from the benzimidazole class and from its own crystal forms.\nplain_language: At the highest dose one patient in six developed liver enzyme rises that reversed on stopping.\norganism: Human\ntissue_or_cell_type: Brain\nexperimental_model: Single-centre dose-escalation and safety study in 24 patients with newly diagnosed high-grade glioma\nlimitations: The only human oncology record here. It is a single-arm dose-escalation and safety study without a control group, so the survival figures cannot be read as efficacy.\nexposure: Oral mebendazole at 25, 50, 100 and 200 milligrams per kilogram per day with adjuvant temozolomide, with trough plasma levels at 4, 8 and 16 weeks\nevidence_span: {\"source_cache\": \"artifacts/mebendazole-research/33506200.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"ab5f2c1d14ccb7fa9f690201326bdbfcab3e07758bc78b76ff9adec2ca774ec6\", \"start_char\": 0, \"end_char\": 1712, \"text_sha256\": \"ab5f2c1d14ccb7fa9f690201326bdbfcab3e07758bc78b76ff9adec2ca774ec6\"}\n[mbz-p33506200] Mebendazole and temozolomide in patients with newly diagnosed high-grade gliomas: results of a phase 1 clinical trial. (2021). https://pubmed.ncbi.nlm.nih.gov/33506200/ DOI: 10.1093/noajnl/vdaa154","model_system":"Single-centre dose-escalation and safety study in 24 patients with newly diagnosed high-grade glioma","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [mbz-p33506200] Mebendazole and temozolomide in patients with newly diagnosed high-grade gliomas: results of a phase 1 clinical trial. (2021). https://pubmed.ncbi.nlm.nih.gov/33506200/ DOI: 10.1093/noajnl/vdaa154","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"06104773-03d0-5e5c-b9da-eb484e7be657","stable_key":"import-f2ec2007-88ff-5a96-a73b-8b5085e9cea9","title":"Mebendazole: the tubulin it binds, why that is selective, the crystal form that decides whether any of it works, and the off-target that became an oncology programme (2026-09-22)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"58b652636677e5033fd1dd555744485fcef18f21a97dcf68723fe072b656f413","revision_id":"a2cd9c22-0549-52ca-a653-8a0c2362ec85","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}